Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
- PMID: 33019930
- DOI: 10.2174/1566523220666201005110726
Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
Abstract
In recent years, RNA interference technology has been extensively studied for its therapeutic potential against a wide variety of diseases. It aims to silence the expression of undesired genes associated with the target disease by the administration of RNA interference agents. However, these agents (nucleic acids) are unstable in the circulatory system and lack target specificity. Drug delivery systems are, therefore, crucial for the successful practice of the technique. A wide array of delivery systems has been developed to conquer these challenges, such as viral vectors, inorganic drug carriers, polymeric carriers and lipid-based carriers, with, however, significant limitations. In addition to the existing technologies, novel, innovative drug delivery systems, such as the configurable xenobot, are emerging at a rapid pace and have the potential to take the realm of biomedicine to the next level. This review summarizes technical difficulties in the development of drug delivery systems and current technologies developed for delivering RNAi agents with a discussion on their limitations.
Keywords: RNA interference; albumin; exosome; liposome; nucleic acid delivery; viral vector; xenobot.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics.ACS Nano. 2025 Feb 4;19(4):4039-4083. doi: 10.1021/acsnano.4c11858. Epub 2025 Jan 21. ACS Nano. 2025. PMID: 39834294 Review.
-
Lipid and polymeric carrier-mediated nucleic acid delivery.Expert Opin Drug Deliv. 2010 Oct;7(10):1209-26. doi: 10.1517/17425247.2010.513969. Expert Opin Drug Deliv. 2010. PMID: 20836625 Free PMC article. Review.
-
Imaging Functional Nucleic Acid Delivery to Skin.Methods Mol Biol. 2016;1372:1-24. doi: 10.1007/978-1-4939-3148-4_1. Methods Mol Biol. 2016. PMID: 26530911
-
To be targeted: is the magic bullet concept a viable option for synthetic nucleic acid therapeutics?Hum Gene Ther. 2011 Jul;22(7):799-807. doi: 10.1089/hum.2011.065. Epub 2011 Jun 17. Hum Gene Ther. 2011. PMID: 21563983 Review.
-
Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond).Chem Rev. 2015 Oct 14;115(19):11043-78. doi: 10.1021/cr5006793. Epub 2015 Apr 15. Chem Rev. 2015. PMID: 25872804 Review. No abstract available.
Cited by
-
The role of miRNA in retinal ganglion cell health and disease.Neural Regen Res. 2022 Mar;17(3):516-522. doi: 10.4103/1673-5374.320974. Neural Regen Res. 2022. PMID: 34380881 Free PMC article. Review.
-
Liposomal siRNA Formulations for the Treatment of Herpes Simplex Virus-1: In Vitro Characterization of Physicochemical Properties and Activity, and In Vivo Biodistribution and Toxicity Studies.Pharmaceutics. 2022 Mar 13;14(3):633. doi: 10.3390/pharmaceutics14030633. Pharmaceutics. 2022. PMID: 35336008 Free PMC article.
-
Exploring the Potentials of Hyaluronic Acid-coated Polymeric Nanoparticles in Enhanced Cancer Treatment by Precision Drug Delivery, Tackling Drug Resistance, and Reshaping the Tumour Micro Environment.Curr Med Chem. 2025;32(20):3960-3999. doi: 10.2174/0109298673302510240328050115. Curr Med Chem. 2025. PMID: 38571347 Review.
-
Targeting ANGPTL3 by GalNAc-conjugated siRNA ANGsiR10 lowers blood lipids with long-lasting and potent efficacy in mice and monkeys.Mol Ther Nucleic Acids. 2022 Dec 5;31:68-77. doi: 10.1016/j.omtn.2022.11.023. eCollection 2023 Mar 14. Mol Ther Nucleic Acids. 2022. PMID: 36618267 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical